FDA Approves Omnaris for Hay Fever

New nasal spray improves symptoms of seasonal and perennial allergies

MONDAY, Oct. 23 (HealthDay News) -- The U.S. Food and Drug Administration has approved the nasal spray Omnaris (ciclesonide) for the treatment of seasonal and perennial allergic rhinitis among adults and children aged 12 and older.

Manufactured by ALTANA Pharma US, Inc. of Florham Park, N.J., Omnaris is a corticosteroid. However, exactly how it relieves hay fever is not known, according to the FDA.

The approval of Omnaris was based on results of four randomized, placebo-controlled trials lasting from two weeks to one year. Patients treated with the new nasal spray showed an 8 percent to 10 percent greater reduction in nasal symptoms including runny nose, nasal itching, sneezing and nasal congestion, compared to their counterparts who received placebo.

Side effects included headache, nosebleeds and inflammation of the nose and throat linings.

More Information

Physician's Briefing